Compare MP Materials (MP) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance

MP MaterialsTrade

Relay Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

MP Materials vs Relay Therapeutics Inc. Common Stock — how do they compare? MP Materials trades at $46.72 (market cap $8.22B), while Relay Therapeutics Inc. Common Stock trades at $17.46 (market cap $3.82B). The key difference: MP Materials is far larger — about 2.2× Relay Therapeutics Inc. Common Stock's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, MP Materials nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MP Materials for 11 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.

	MP	RLAY
Market Cap	$8.22B	$3.82B
Volume	5,457,792	4,332,079
Sector	Basic Materials	Health
52-Week High	$98.65	$20.75
52-Week Low	$38.10	$6.03
Typical Hold Time	11 Days	0 Days
Enterprise Value	$7.70B	$2.93B

View details →View details →

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

81% Buy19% Sell

Avg holding period · 11 Days

RLAY

100% Buy0% Sell

Avg holding period · 0 Days

Top news

Latest headlines on both assets

Critical metals stocks fall again; builders like USA Rare Earth drop sharply, producers like MP Materials hold better.24/7 Wall Street · 22 hours agoBearish Rare earth stocks drop 3-5% amid sector-wide selloff without company-specific news.24/7 Wall Street · 2 days agoBearish Pentagon invests $400M in MP Materials to break China's rare earth magnet monopoly, GM first to receive non-China magnets.24/7 Wall Street · 4 days agoBullish View details →

RLAY

View details →

About MP Materials

MP Materials mines, refines, and manufactures rare earth materials and magnets in the United States. Its products are used in transportation, energy, robotics, defense, and aerospace applications.

About Relay Therapeutics Inc. Common Stock

Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.